HHS Secretary Xavier Becerra (Patrick Semansky/AP Images)

Leg­is­la­tors call HHS to ac­tion on Xtan­di march-in rights

More than two dozen law­mak­ers are putting re­newed pres­sure on the fed­er­al gov­ern­ment to use its march-in rights to low­er the price of prostate can­cer drug Xtan­di.

The group — led by Sens. Eliz­a­beth War­ren (D-MA) and An­gus King (I-ME), and Rep. Lloyd Doggett (D-TX) — penned a let­ter to HHS Sec­re­tary Xavier Be­cer­ra on Tues­day re­quest­ing a “long over­due” pub­lic hear­ing on a pe­ti­tion to low­er Xtan­di’s price filed by pa­tients more than a year ago. Ear­li­er this month, the pe­ti­tion­ers got word that the NIH is still “cur­rent­ly co­or­di­nat­ing with HHS to re­view and as­sess the in­for­ma­tion,” ac­cord­ing to the let­ter.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.